We are thrilled to announce our recent investment in Radar Therapeutics which has successfully closed an oversubscribed $13.4 million Series Seed round. The round was led by NFX, with participation from Eli Lilly and Company, KdT Ventures, among others. Radar Therapeutics is pioneering next-generation cell-specific expression control of RNA therapeutics utilising the ADAR editing technology developed by its co-founders. https://lnkd.in/egadu_vS
Biovision Ventures
Directeurs du capital-risque et du capital-investissement
VC firm investing in early-stage therapeutics and digital health startups in the US and Europe
À propos
We are a Venture Capital firm investing in early-stage therapeutics and digital health opportunities in the US and Europe
- Site web
-
https://www.biovision.vc
Lien externe pour Biovision Ventures
- Secteur
- Directeurs du capital-risque et du capital-investissement
- Taille de l’entreprise
- 2-10 employés
- Siège social
- Luxembourg
- Type
- Société civile/Société commerciale/Autres types de sociétés
Lieux
-
Principal
Obtenir l’itinéraire
Luxembourg, LU
Employés chez Biovision Ventures
Nouvelles
-
We're looking forward to meeting old friends and new connections at 2024 BIO International Convention! Alexey Konov, the Managing Partner at Biovision Ventures, will also be speaking at "All Money is NOT Created Equal: The Differences between Angel, Venture and Strategic Capital in the Biotech Funding Ecosystem" panel on June 3rd at 1:45pm, alongside Yaniv Sneor, Max Farina, MD, and Jonathan McClain.
All Money is NOT Created Equal: The Differences between Angel, Venture and Strategic Capital in the Biotech Funding Ecosystem
convention.bio.org